Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer in the Era of Personalized Medicine
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.